Andrew John Hugh Macintyr Sims Acquires 20,000 Shares of Plus Therapeutics (NASDAQ:PSTV) Stock

Plus Therapeutics, Inc. (NASDAQ:PSTV) CFO Andrew John Hugh Macintyr Sims acquired 20,000 shares of the firm’s stock in a transaction on Tuesday, November 4th. The stock was purchased at an average price of $0.51 per share, with a total value of $10,200.00. Following the transaction, the chief financial officer owned 68,138 shares of the company’s stock, valued at approximately $34,750.38. This trade represents a 41.55% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

Plus Therapeutics Stock Down 4.9%

NASDAQ:PSTV opened at $0.51 on Friday. Plus Therapeutics, Inc. has a 52 week low of $0.16 and a 52 week high of $2.31. The stock’s 50-day moving average price is $0.57 and its 200-day moving average price is $0.50. The stock has a market capitalization of $51.00 million, a PE ratio of -0.23 and a beta of 0.77.

Plus Therapeutics (NASDAQ:PSTV) last issued its quarterly earnings results on Thursday, October 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.02). The business had revenue of $1.40 million during the quarter, compared to the consensus estimate of $1.50 million. Sell-side analysts expect that Plus Therapeutics, Inc. will post -2.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Plus Therapeutics

Large investors have recently made changes to their positions in the stock. Virtu Financial LLC acquired a new stake in shares of Plus Therapeutics in the 1st quarter worth $38,000. Jane Street Group LLC purchased a new stake in shares of Plus Therapeutics in the second quarter valued at about $41,000. Finally, Altium Capital Management LLC acquired a new stake in Plus Therapeutics during the third quarter worth about $628,000. 3.28% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Zacks Research raised shares of Plus Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, October 13th. Ascendiant Capital Markets raised their price target on shares of Plus Therapeutics from $20.50 to $21.00 and gave the company a “buy” rating in a research note on Monday, October 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Plus Therapeutics in a research note on Wednesday, October 8th. D Boral Capital upgraded Plus Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, September 3rd. Finally, Maxim Group dropped their price target on Plus Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research report on Monday, August 18th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $7.75.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.